Should I Buy ACU? ACU 2026 Analysis

Should You Buy Acme United Corp (ACU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

44.610

1 Day change

1.34%

52 Week Range

45.250

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: no proprietary buy signals, momentum is weakening, and pattern-based probabilities skew negative over 1-week to 1-month.
With an impatient approach (acting now), ACU doesn’t offer a compelling immediate upside setup; risk/reward favors reducing exposure or staying out.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Influential/political activity: No recent congress trading data available; insiders show no notable recent trend.

Technical Analysis

Trend/momentum: MACD histogram is negative (-0.131) and still below zero (bearish), though “negatively contracting” suggests downside momentum may be slowing rather than reversing.
RSI (6): 61.23 (neutral-to-slightly bullish), not an oversold bounce setup.
Moving averages: converging (indecision/transition), not a clean uptrend confirmation.
Levels: Pivot 42.47 is the key near-term line; price at 43.20 is only modestly above pivot.
- Resistance: 44.15 (R1), then 45.19 (R2).
- Support: 40.79 (S1), then 39.75 (S2).
Forward pattern read: Similar candlestick-pattern analysis implies ~70% odds of drift lower (next day -0.53%, next week -1.49%, next month -9.51%), which argues against buying now.

Positive Catalysts

- Gross margin improved in 2025/Q3 (39.12, up YoY), indicating better product mix/pricing or cost control.
- Upcoming earnings event: QDEC 2025 earnings on 2026-02-27 (pre-market) could act as a catalyst if results/guide beat expectations.
- RSI is not overbought and price is above the pivot, leaving room for a push toward 44.15 if buyers step in.

Neutral/Negative Catalysts

- Earnings quality deterioration in the latest reported quarter (2025/Q3): net income and EPS both down ~14–15% YoY despite revenue growth.
- Technicals are not confirming a bullish move (MACD below zero; moving averages converging), increasing odds of chop-to-downside.
- No supportive flow signals: hedge funds neutral; insiders neutral; no notable news catalyst in the past week.
- Pattern-based outlook points to further weakness over the next month (median expectation skewing meaningfully negative).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 49.063M, +1.86% YoY (modest top-line growth).
Net Income: 1.903M, -14.51% YoY (profitability declined).
EPS: 0.46, -14.81% YoY (shareholder earnings pressure).
Gross Margin: 39.12, up YoY (a relative bright spot), but not enough to prevent EPS decline—suggests higher operating costs/other expenses below gross profit.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data provided in the dataset.
Wall Street pros/cons view (based on available data only):
- Pros: steady revenue growth; improving gross margin.
- Cons: declining net income/EPS; lack of bullish technical confirmation; no near-term sentiment/catalyst support in news/flow data.

Analyst Rating

Wall Street analysts forecast ACU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACU is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold